Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3Gastrointestinal 2Sarcoma 1Myeloid 1Head & Neck 1Gynecologic 1Genitourinary 1Classical hematology 1CNS 1Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Head and Neck Neoplasms 1

Interventions

pembrolizumab 65Cisplatin 42Cetuximab 36Radiotherapy 28Nivolumab 26Paclitaxel 22Carboplatin 22Docetaxel 20durvalumab 14Radiotherapy, Intensity-Modulated 12Fluorouracil 12Cyclophosphamide 10tremelimumab 9Gemcitabine 9Ipilimumab 8avelumab 7Erlotinib Hydrochloride 7toripalimab 6fludarabine 6epacadostat 6cemiplimab 6Radiosurgery 6Interleukin-2 6Capecitabine 6Bevacizumab 6spartalizumab 5Celecoxib 5zalutumumab 4tislelizumab 4fludarabine phosphate 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Microarray Analysis × Head & Neck × Clear all
NCT00357617 2010-12-24

Celecoxib in Treating Patients With Head and Neck Cancer That Can Be Removed By Surgery

National Cancer Institute (NCI)

Phase 1/2 Unknown
24 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡